Cardiac Atrophy and Heart Failure In Cancer

via the ubiquitin-proteosome system. Further to direct effects of malignancy on the heart, several chemotherapeutic agents are known to affect the myocardium, in particular the anthracyclines. The aim of this report is to review the effects of cancer and cancer treatment on the heart and what is known about the underlying mechanisms. Furthermore, clinical strategies to limit and treat cancer-associated cardiac atrophy are discussed, emphasising the benefit of a multidisciplinary approach by cardiologists and oncologists to optimise models of care to improve outcomes for patients with cancer.

[1]  S. Lipshultz,et al.  Prevention of cardiotoxicity among survivors of childhood cancer , 2017, British journal of clinical pharmacology.

[2]  Jennifer H. Jordan,et al.  Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors , 2016, Circulation. Cardiovascular imaging.

[3]  E. Hirsch,et al.  New signal transduction paradigms in anthracycline-induced cardiotoxicity. , 2016, Biochimica et biophysica acta.

[4]  S. Anker,et al.  Megestrol acetate improves cardiac function in a model of cancer cachexia‐induced cardiomyopathy by autophagic modulation , 2016, Journal of cachexia, sarcopenia and muscle.

[5]  K. Murphy.  The pathogenesis and treatment of cardiac atrophy in cancer cachexia. , 2016, American journal of physiology. Heart and circulatory physiology.

[6]  P. Burridge,et al.  Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells , 2015, Current protocols in human genetics.

[7]  Guido Strunk,et al.  Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality , 2015, Heart.

[8]  S. Powers,et al.  Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin‐induced cardiac and skeletal muscle myopathy , 2015, The Journal of physiology.

[9]  P. Thavendiranathan,et al.  Cardiotoxicity Due to Chemotherapy: Role of Cardiac Imaging , 2015, Current Cardiology Reports.

[10]  A. Dogan,et al.  Protective effects of spironolactone against anthracycline‐induced cardiomyopathy , 2015, European journal of heart failure.

[11]  O. Bergmann,et al.  Cardiac regeneration in vivo: mending the heart from within? , 2014, Stem cell research.

[12]  J. Radford,et al.  An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  S. Anker,et al.  Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. , 2014, European heart journal.

[14]  X. Cen,et al.  Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. , 2014, Biochemical pharmacology.

[15]  Randolph P. Martin,et al.  Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. , 2014, Journal of the American College of Cardiology.

[16]  J. Mackey,et al.  Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy , 2014, Breast Cancer Research and Treatment.

[17]  S. Flamm,et al.  Cardiac MRI in the Assessment of Cardiac Injury and Toxicity From Cancer Chemotherapy: A Systematic Review , 2013, Circulation. Cardiovascular imaging.

[18]  P. Lewandowski,et al.  Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice , 2013, Journal of cachexia, sarcopenia and muscle.

[19]  M. Bansal.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013 .

[20]  B. Loos,et al.  Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity. , 2013, Toxicology.

[21]  E. Blough,et al.  Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse , 2013, International journal of oncology.

[22]  R. Kwong,et al.  Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. , 2012, The American journal of cardiology.

[23]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[24]  S. Kutty,et al.  Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[25]  H. Crijns,et al.  Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. , 2012, Journal of molecular and cellular cardiology.

[26]  L. Malvestio,et al.  Calpain‐mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin‐induced cardiomyopathy , 2011, European journal of pharmacology.

[27]  Stian Lydersen,et al.  Physical exercise for cancer patients with advanced disease: a randomized controlled trial. , 2011, The oncologist.

[28]  Y. Nishijima,et al.  Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. , 2011, International journal of oncology.

[29]  T. Byers,et al.  Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study , 2011, Breast Cancer Research.

[30]  L. Leinwand,et al.  Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. , 2011, Cancer research.

[31]  Stephan von Haehling,et al.  Cachexia as a major underestimated and unmet medical need: facts and numbers , 2010, Journal of cachexia, sarcopenia and muscle.

[32]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[33]  D. Aggarwal,et al.  Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. , 2009, Biophysical journal.

[34]  D. K. Shakir,et al.  Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management , 2009, Journal of clinical medicine research.

[35]  Y. Fujio,et al.  Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. , 2008, Cardiovascular research.

[36]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[37]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[38]  D. Pennell,et al.  Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. , 2002, The American journal of cardiology.

[39]  J. Schulz-Menger,et al.  Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. , 2001, American heart journal.

[40]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[41]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[42]  H. Pouleur,et al.  Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. , 1989, American heart journal.

[43]  R. Brasseur,et al.  Study of the adriamycin-cardiolipin complex structure using attenuated total reflection infrared spectroscopy. , 1987, Biochemistry.

[44]  J. Mason,et al.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. , 1981, American heart journal.

[45]  D. V. Von Hoff,et al.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. , 1977, The American journal of medicine.

[46]  G. Burch,et al.  The cachetic heart. A clinico-pathologic, electrocardiographic and roentgenographic entity. , 1968, Diseases of the chest.

[47]  A. Katz,et al.  DISEASE OF THE HEART IN THE WORKS OF HIPPOCRATES , 1962, British heart journal.

[48]  P. Mateo,et al.  Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. , 2015, Circulation. Heart failure.

[49]  D. Renlund,et al.  Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. , 1995, American heart journal.

[50]  V. Ferrans,et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.